Brief: Compugen Doses First Patient In Com701/Opdivo® Phase 1B Cohort Expansion Study
30/06/2021 12:15
June 30 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN DOSES FIRST PATIENT IN COM701/OPDIVO® (NIVOLUMAB)
PHASE
1B COHORT EXPANSION STUDY
Source text for Eikon: ID:nPn68Jy1Ja
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025